Potential new approach to the treatment of multiple sclerosis

A prospective new method of treating patients with multiple sclerosis has been proposed by researchers of the Mainz University Medical Center working in cooperation with researchers of the University of Montreal. In model trials and experiments employing human endothelial cells, they discovered that the EGFL7 protein hinders the migration of immune cells into the central nervous system by stabilizing the blood-brain barrier. These findings have recently been published in Nature Communications.

The autoimmune disease multiple sclerosis (MS) is one of the most common disorders that cause disabilities in young adults in industrialized countries. In MS, the body's own immune system attacks the central nervous system (CNS). Immune cells (T cells) cross the blood-brain barrier, i.e., the physiological barrier between the blood circulatory system and the CNS, enter the brain, and damage the protective covering of the nerve fibers, the myelin layer. This results in the degeneration and loss of function of nerve cells and leads to neurological disability-related symptoms.

The primary aim of MS research is to develop new treatments that will prevent this pathological process. Putting the EGFL7 protein at the focus of their research, the team led by Dr. Timo Uphaus and Professor Frauke Zipp of the Department of Neurology at the University Medical Center of Johannes Gutenberg University Mainz collaborated with Dr. Catherine Larochelle of the University of Montreal and Professor Mirko Schmidt and researchers of the German Cancer Consortium (DKTK). They chose a completely innovative pathophysiological-based approach as EGFL7 had not previously been considered of relevance to MS research. However, it has been shown, for example in the case of breast cancer, that EGFL7 does have an influence on the migration of immune cells into tumor tissue. Since the migration of immune cells into the brain plays a significant role in MS, the researchers decided to investigate this protein and whether it could also have an effect on the autoimmune disorder. Notably, on the basis of their results they were able to demonstrate a possible new approach to successfully treat MS.

The researchers discovered that CNS inflammation was accompanied by an increased release of EGFL7. Immune cells subsequently bind to EGFL7, in a sense being taken prisoner so that they are prevented from crossing into the CNS. EGFL7 is released by the endothelial cells of the blood-brain barrier and causes immune cells to be retained in the perivascular space. In their model trials, the researchers next found that exposure to EGLF7 makes the blood-brain barrier less permeable. In the presence of this more effective barrier, the passage of immune cells into the CNS was reduced. This counteracted the corresponding pathological mechanisms and thus led to improvements in clinical symptoms.

Furthermore, the researchers were able to confirm their experimental findings in a human blood-brain barrier model, where there was also decreased migration of immune cells in isolated human endothelial cells. They now conclude that it might be possible in principle to take advantage of the way that EGFL7 inhibits the migration of immune cells into the CNS and enhances the impenetrability of the blood-brain barrier for the treatment of multiple sclerosis.

Catherine Larochelle, Timo Uphaus, Bieke Broux, Elizabeth Gowing, Magdalena Paterka, Laure Michel, Nevenka Dudvarski Stankovic, Frank Bicker, Florent Lemaître, Alexandre Prat, Mirko H. H. Schmidt, Frauke Zipp.
EGFL7 reduces CNS inflammation in mouse.
Nature Communicationsvolume 9, Article number: 819 (2018). doi: 10.1038/s41467-018-03186-z.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...